Literature DB >> 34062483

Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036.

Claus Garbe1, Ulrike Keim2, Sara Gandini3, Teresa Amaral4, Alexander Katalinic5, Bernd Hollezcek6, Peter Martus7, Lukas Flatz2, Ulrike Leiter2, David Whiteman8.   

Abstract

OBJECTIVES: Cutaneous melanoma (CM) and keratinocyte cancer (KC) cause considerable morbidity and mortality. We analysed long-term trends of CM and KC in different white populations.
MATERIAL AND METHODS: Age-standardised (European Standard Population 2013) incidence and mortality rates (ASIR, ASMR) of CM were extracted from cancer registries in Denmark, New Zealand and the US SEER-Database. ASIRs of KC were sourced from registries of the German federal states Saarland and Schleswig-Holstein, and from Scotland. Age-period-cohort models were used to project melanoma incidence trends.
RESULTS: In Denmark between 1943 and 2016, melanoma ASIR increased from 1.1 to 46.5 in males, and from 1.0 to 48.5 in females, estimated to reach 60.0 and 73.1 in males and females by 2036. Melanoma mortality in Denmark (1951-2016) increased from 1.4 to 6.7 (males) and 1.2 to 3.7 (females). In New Zealand between 1948 and 2016, ASIR increased from 2.7 to 81.0 (males) and from 3.8 to 54.7 (females), slight declines are estimated by 2036 for both genders. Melanoma mortality increased six-fold in New Zealand males between 1950 and 2016; smaller increases were observed in females. We observed three- to four-fold increases in melanoma incidence in US whites, predicted to rise to 56.1 and 36.2 in males and females until 2036. Melanoma mortality also increased among US whites between 1970 and 2017, female melanoma mortality remained stable. Similar trends are shown for KC.
CONCLUSIONS: In white populations, incidence of CM and KC significantly increased. CM incidence continues to rise in the short term but is predicted to decline in future.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Denmark; Germany; Incidence; Keratinocyte cancer; Melanoma; Mortality; New Zealand; Scotland; United States of America; White-skinned population

Year:  2021        PMID: 34062483     DOI: 10.1016/j.ejca.2021.04.029

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Using the Prediction Model Risk of Bias Assessment Tool (PROBAST) to Evaluate Melanoma Prediction Studies.

Authors:  Isabelle Kaiser; Sonja Mathes; Annette B Pfahlberg; Wolfgang Uter; Carola Berking; Markus V Heppt; Theresa Steeb; Katharina Diehl; Olaf Gefeller
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

2.  Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.

Authors:  Melina Arnold; Deependra Singh; Mathieu Laversanne; Jerome Vignat; Salvatore Vaccarella; Filip Meheus; Anne E Cust; Esther de Vries; David C Whiteman; Freddie Bray
Journal:  JAMA Dermatol       Date:  2022-05-01       Impact factor: 11.816

3.  Identification of significant genes with a poor prognosis in skin cutaneous malignant melanoma based on a bioinformatics analysis.

Authors:  Jin Wang; Jilong Yang
Journal:  Ann Transl Med       Date:  2022-04

4.  Environmental effects of stratospheric ozone depletion, UV radiation, and interactions with climate change: UNEP Environmental Effects Assessment Panel, Update 2021.

Authors:  P W Barnes; T M Robson; P J Neale; C E Williamson; R G Zepp; S Madronich; S R Wilson; A L Andrady; A M Heikkilä; G H Bernhard; A F Bais; R E Neale; J F Bornman; M A K Jansen; A R Klekociuk; J Martinez-Abaigar; S A Robinson; Q-W Wang; A T Banaszak; D-P Häder; S Hylander; K C Rose; S-Å Wängberg; B Foereid; W-C Hou; R Ossola; N D Paul; J E Ukpebor; M P S Andersen; J Longstreth; T Schikowski; K R Solomon; B Sulzberger; L S Bruckman; K K Pandey; C C White; L Zhu; M Zhu; P J Aucamp; J B Liley; R L McKenzie; M Berwick; S N Byrne; L M Hollestein; R M Lucas; C M Olsen; L E Rhodes; S Yazar; A R Young
Journal:  Photochem Photobiol Sci       Date:  2022-02-21       Impact factor: 4.328

5.  Reporting Quality of Studies Developing and Validating Melanoma Prediction Models: An Assessment Based on the TRIPOD Statement.

Authors:  Isabelle Kaiser; Katharina Diehl; Markus V Heppt; Sonja Mathes; Annette B Pfahlberg; Theresa Steeb; Wolfgang Uter; Olaf Gefeller
Journal:  Healthcare (Basel)       Date:  2022-01-26

6.  A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.

Authors:  Naoya Yamazaki; Taiki Isei; Yoshio Kiyohara; Hiroshi Koga; Takashi Kojima; Tatsuya Takenouchi; Kenji Yokota; Kenjiro Namikawa; Min Yi; Alissa Keegan; Satoshi Fukushima
Journal:  Cancer Sci       Date:  2022-06-30       Impact factor: 6.518

7.  Impact of the COVID-19 Pandemic on the Diagnosis and Prognosis of Melanoma.

Authors:  Antonio Martinez-Lopez; Pablo Diaz-Calvillo; Carlos Cuenca-Barrales; Trinidad Montero-Vilchez; Manuel Sanchez-Diaz; Agustin Buendia-Eisman; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

8.  The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.

Authors:  Federica Zamagni; Lauro Bucchi; Silvia Mancini; Emanuele Crocetti; Luigino Dal Maso; Stefano Ferretti; Annibale Biggeri; Simona Villani; Flavia Baldacchini; Orietta Giuliani; Alessandra Ravaioli; Rosa Vattiato; Angelita Brustolin; Giuseppa Candela; Simona Carone; Giuliano Carrozzi; Rossella Cavallo; Ylenia Maria Dinaro; Margherita Ferrante; Silvia Iacovacci; Guido Mazzoleni; Antonino Musolino; Roberto Vito Rizzello; Diego Serraino; Fabrizio Stracci; Rosario Tumino; Carla Masini; Laura Ridolfi; Giuseppe Palmieri; Ignazio Stanganelli; Fabio Falcini
Journal:  Br J Dermatol       Date:  2022-05-31       Impact factor: 11.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.